Abstract
The dorsomedial hypothalamic nucleus harbors leptin sensitive neurons and is intrinsically connected to hypothalamic nuclei involved in feeding behavior. However, it also receives ascending input from the visceroceptive neurons of the brainstem. We have identified a unique glucagon-like-peptide-2 containing neuronal pathway connecting the nucleus of the solitary tract with the dorsomedial hypothalamic nucleus. A glucagon-like-peptide-2 fiber plexus targets neurons expressing its receptor within the dorsomedial hypothalamic nucleus. Pharmacological and behavioral studies confirmed that glucagon-like-peptide-2 signaling is a specific transmitter inhibiting rodent feeding behavior and with potential long-term effects on body weight homeostasis. The glucagon-like-peptide-1 receptor antagonist, Exendin (9–39) is also a functional antagonist of centrally applied glucagon-like-peptide-2.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holst, J.J. Enteroglucagon. Annu. Rev. Physiol. 59, 257–271 (1997).
Drucker, D.J. Glucagon-like peptides. Diabetes 47, 159 –169 (1998).
Tang-Christensen, M. et al. Central administration of GLP-1(7–36)amide inhibits food and water intake in rats. Am. Jour. Phys. 271, 848–856 (1996).
Larsen, P.J., Tang-Christensen, M. & Jessop, D. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138, 4445–4455 (1997).
Tang-Christensen, M., Vrang, N. & Larsen, P.J. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47, 530–537 (1998).
Gunn, I. et al. Central glucagon-like peptide-I in the control of feeding. Biochem. Soc Trans. 24, 581–584 (1996).
McMahon, L.R. & Wellman, P.J. PVN infusion of GLP-1-(7–36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 274, R23– R29 (1998).
Turton, M.D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69– 72 (1996).
Rinaman, L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am. J. Physiol. 277, R1537–R1540 (1999).
Seeley, R.J. et al. The role of CNS glucagon-like peptide-1 (7–36) amide receptors in mediating the visceral illness effects of lithium chloride. J. Neurosci. 20, 1616–1621 (2000).
Munroe, D.G. et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 96, 1569–1573 (1999).
Larsen, P.J., Tang-Christensen, M., Holst, J.J. & Orskov, C. Distribution of glucagon-like peptide-1 and other preproglucagon- derived peptides in the rat hypothalamus and brainstem. Neuroscience 77, 257–270 (1997).
Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261–280 ( 1999).
Paxinos, G. & Watson, C. in The rat brain- in stereotxic coordinates 4th ed. 30–35 (Academic Press, San Diego, California, 1998).
Schwartz, M.W. et al. Insulin, neuropeptide Y, and food intake. Ann. N.Y. Acad. Sci. 692, 60–71 (1993).
Stanley, B.G. & Leibowitz, S.F. Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc. Natl. Acad. Sci. USA 82, 3940– 3943 (1985).
Valverde, I. et al. Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 132, 75–79 (1993).
Thorens, B. et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes 42, 1678–1682 (1993).
Brubaker, P.L. et al. Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2. Endocrinology 138, 4837–4843 (1997).
Schepp, W. et al. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7–36)NH2. Digestion 57, 398–405 ( 1996).
Van Dijk, G. et al. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am. J. Physiol. 271 , R1096–R1100 (1996).
Thiele, T.E. et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am. J. Physiol. 272, R726–R730 (1997).
Yusta, B. et al. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor . J. Biol. Chem. 274, 30459– 30467 (1999).
Schepp, W. et al. Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2. Eur. J. Pharmacol. 269, 183–191 (1994).
Serre, V. et al. Exendin (9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology 139, 4448–4454 (1998).
Ørskov, C. et al. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J. Biol. Chem. 264, 12826–12829 (1989).
Bernardis, L.L. & Bellinger, L.L. The dorsomedial hypothalamic nucleus revisited: 1998 update. Proc. Soc. Exp. Biol. Med. 218, 284–306 ( 1998).
Ter Horst, G.J. & Luiten, P.G. Phaseolus vulgaris leuco-agglutinin tracing of intrahypothalamic connections of the lateral, ventromedial, dorsomedial and paraventricular hypothalamic nuclei in the rat . Brain Res. Bull. 18, 191– 203 (1987).
Elmquist, J.K. et al. Leptin activates neurons in ventrobasal hypothalamus and brainstem . Endocrinology 138, 839– 842 (1997).
Pelletier, G. Ultrastructural localization of neuropeptide Y in the hypothalamus. Ann. N.Y. Acad. Sci. 611, 232–246 (1990).
Li, C., Chen, P. & Smith, M.S. The acute suckling stimulus induces expression of neuropeptide Y (NPY) in cells in the dorsomedial hypothalamus and increases NPY expression in the arcuate nucleus. Endocrinology 139, 1645–1652 (1998).
Li, C., Chen, P. & Smith, M.S. Neuropeptide Y (NPY) neurons in the arcuate nucleus (ARH) and dorsomedial nucleus (DMH), areas activated during lactation, project to the paraventricular nucleus of the hypothalamus (PVH). Regul. Pept. 75–76, 93–100 ( 1998).
Smith, M.S. Lactation alters neuropeptide-Y and proopiomelanocortin gene expression in the arcuate nucleus of the rat. Endocrinology 133, 1258–1265 (1993).
Wilding, J.P., Ajala, M.O., Lambert, P.D. & Bloom, S.R. Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. J. Endocrinol. 152, 365–369 (1997).
Kesterson, R.A. et al. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol. Endocrinol. 11, 630–637 (1997)
Thim, L. et al. Purification and characterisation of a new hypothalamic satiety peptide, cocaine and amphetamine regulated transcript (CART), produced in yeast. FEBS Lett. 428, 263– 268 (1998).
Kristensen, P., Eriksen, J. & Dano, K. Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J. Histochem. Cytochem. 39, 341–349 ( 1991).
Jensen, J. et al. mRNA profiling of rat islet tumors reveals nkx 6.1 as a beta-cell- specific homeodomain transcription factor. J. Biol. Chem. 271, 18749–18758 (1996).
Woldbye, D.P. et al. Prolonged induction of c-fos in neuropeptide Y- and somatostatin-immunoreactive neurons of the rat dentate gyrus after electroconvulsive stimulation. Brain. Res. 720, 111–119 (1996).
Vrang, N., Larsen, P.J., Clausen, J.T. & Kristensen, P. Neurochemical characterization of hypothalamic cocaine-amphetamine- regulated transcript neurons J. Neurosci. 19, RC5 (1999).
Acknowledgements
The authors thank L. Thim and J.T. Clausen, Novo Nordisk, Bagsværd, Denmark, for helpful suggestions and for the gift of recombinant GLP-2 and GLP-2 antibody. J. Mandelbaum, Novo Nordisk A/S, Bagsværd, and G. Hahn, Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark, are deeply thanked for excellent technical assistance. This study was made possible by generous grants from the Danish Diabetes Association, The Novo Nordisk Foundation, The Danish Medical Research Council (# 9701798), The Danish Research Foundation to the Biotechnology Centre for Cellular Communication, Direktør Jacob og hustru Olga Madsen Foundation and Fonden til Laegevidenskabens fremme. M. Tang-Christensen is supported by a research grant from the Michaelsen Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tang-Christensen, M., Larsen, P., Thulesen, J. et al. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6, 802–807 (2000). https://doi.org/10.1038/77535
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/77535
This article is cited by
-
Glucagon-like peptide-2 rescues memory impairments and neuropathological changes in a mouse model of dementia induced by the intracerebroventricular administration of streptozotocin
Scientific Reports (2019)
-
The prolonged effect of glucagon-like peptide 2 pretreatment on growth performance and intestinal development of weaned piglets
Journal of Animal Science and Biotechnology (2016)
-
Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet
Endocrine (2016)
-
Effects of GLP-1 on appetite and weight
Reviews in Endocrine and Metabolic Disorders (2014)
-
The regulation of food intake by the gut-brain axis: implications for obesity
International Journal of Obesity (2013)